Leveraging MrkA Display on Self-Assembling Protein Nanoparticles for Enhanced Immune Activation

利用自组装蛋白纳米颗粒上的MrkA展示增强免疫激活

阅读:1

Abstract

Self-assembling protein nanoparticles (NPs) offer a versatile platform to enhance antigen immunogenicity through a multivalent display. Klebsiella pneumoniae (Kp) is a critical multidrug-resistant pathogen for which no licensed vaccine exists, posing a significant global health threat. This study aimed to develop and evaluate protein nanoparticle-based vaccine candidates presenting MrkA, a highly conserved type 3 fimbrial subunit and promising Kp vaccine target, to elicit robust protective immune responses. We genetically fused MrkA to four distinct self-assembling protein nanoparticle scaffolds: Helicobacter pylori ferritin, Thermotoga maritima encapsulin, computationally designed mI3, and Mycobacterium tuberculosis dodecin. The resulting MrkA-NPs were expressed and purified, and their structural integrity was confirmed by electron microscopy, dynamic light scattering, and nuclear magnetic resonance spectroscopy. These constructs were then evaluated for their immunogenicity in animal models. All MrkA-displaying NPs significantly enhanced MrkA-specific IgG responses, eliciting significantly higher antibody titers compared to recombinant MrkA. Importantly, passive transfer of immune sera from rabbits immunized with MrkA-dodecin NP conferred significant protection against a lethal Kp challenge, resulting in 90% survival compared to the control group. Our findings confirmed the ability of NPs to significantly enhance the immune responses against a bacterial protein such as MrkA, confirming their potential as transformative tools in vaccine development. This study also offers promising results for the development of a vaccine against Kp, addressing antimicrobial resistance and improving global health.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。